In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma

Amit Kumar Mitra; Harish Kumar; Vijay Ramakrishnan; Li Chen; Linda Baughn; Shaji Kumar; S. Vincent Rajkumar; Brian G. Van Ness

doi:10.1038/s41408-020-00344-9

In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma

Amit Kumar Mitra, Harish Kumar, Vijay Ramakrishnan, Li Chen, Linda Baughn, Shaji Kumar, S. Vincent Rajkumar, Brian G. Van Ness

Research output: Contribution to journal › Article › peer-review

Abstract

Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expression patterns between innate proteasome inhibitor (PI)-sensitive and PI-resistant HMCLs following test dosing with the second-generation PI Ixazomib. We found 1553 genes that changed significantly post treatment in PI-sensitive HMCLs compared with only seven in PI-resistant HMCLs (p < 0.05). Genes that were uniquely regulated in PI-resistant lines were RICTOR (activated), HNF4A, miR-16-5p (activated), MYCN (inhibited), and MYC (inhibited). Ingenuity pathway analysis (IPA) using top kinetic response genes identified the proteasome ubiquitination pathway (PUP), and nuclear factor erythroid 2-related factor 2 (NRF2)-mediated oxidative stress response as top canonical pathways in Ix-sensitive cell lines and patient-derived cells, whereas EIF2 signaling and mTOR signaling pathways were unique to PI resistance. Further, 10 genes were common between our in vitro and ex vivo post-treatment kinetic PI response profiles and Shaughnessy’s GEP80-postBz gene expression signature, including the high-risk PUP gene PSMD4. Notably, we found that heat shock proteins and PUP pathway genes showed significant higher upregulation in Ix-sensitive lines compared with the fold-change in Ix-resistant myelomas.

Original language	English (US)
Article number	78
Journal	Blood cancer journal
Volume	10
Issue number	7
DOIs	https://doi.org/10.1038/s41408-020-00344-9
State	Published - Jul 1 2020

Bibliographical note

Funding Information:
AKM was supported by a grant from the International Myeloma Foundation. We thankfully acknowledge the University of Minnesota Genomics Center and the Minnesota Supercomputing Institute for support with RNA-seq profiling and analysis. This work was further supported by NCI grant# 1U54CA224018-01 (Sub-Project ID: 8404) to BVN.

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

Access

10.1038/s41408-020-00344-9

Fingerprint Dive into the research topics of 'In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma'. Together they form a unique fingerprint.

Cite this

In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. / Mitra, Amit Kumar; Kumar, Harish; Ramakrishnan, Vijay; Chen, Li; Baughn, Linda; Kumar, Shaji; Rajkumar, S. Vincent; Van Ness, Brian G.

In: Blood cancer journal, Vol. 10, No. 7, 78, 01.07.2020.

Research output: Contribution to journal › Article › peer-review

@article{91670cb0295b4a17b73bc8c22055a47f,

title = "In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma",

abstract = "Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expression patterns between innate proteasome inhibitor (PI)-sensitive and PI-resistant HMCLs following test dosing with the second-generation PI Ixazomib. We found 1553 genes that changed significantly post treatment in PI-sensitive HMCLs compared with only seven in PI-resistant HMCLs (p < 0.05). Genes that were uniquely regulated in PI-resistant lines were RICTOR (activated), HNF4A, miR-16-5p (activated), MYCN (inhibited), and MYC (inhibited). Ingenuity pathway analysis (IPA) using top kinetic response genes identified the proteasome ubiquitination pathway (PUP), and nuclear factor erythroid 2-related factor 2 (NRF2)-mediated oxidative stress response as top canonical pathways in Ix-sensitive cell lines and patient-derived cells, whereas EIF2 signaling and mTOR signaling pathways were unique to PI resistance. Further, 10 genes were common between our in vitro and ex vivo post-treatment kinetic PI response profiles and Shaughnessy{\textquoteright}s GEP80-postBz gene expression signature, including the high-risk PUP gene PSMD4. Notably, we found that heat shock proteins and PUP pathway genes showed significant higher upregulation in Ix-sensitive lines compared with the fold-change in Ix-resistant myelomas.",

author = "Mitra, {Amit Kumar} and Harish Kumar and Vijay Ramakrishnan and Li Chen and Linda Baughn and Shaji Kumar and Rajkumar, {S. Vincent} and {Van Ness}, {Brian G.}",

note = "Funding Information: AKM was supported by a grant from the International Myeloma Foundation. We thankfully acknowledge the University of Minnesota Genomics Center and the Minnesota Supercomputing Institute for support with RNA-seq profiling and analysis. This work was further supported by NCI grant# 1U54CA224018-01 (Sub-Project ID: 8404) to BVN.",

year = "2020",

month = jul,

day = "1",

doi = "10.1038/s41408-020-00344-9",

language = "English (US)",

volume = "10",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma

AU - Mitra, Amit Kumar

AU - Kumar, Harish

AU - Ramakrishnan, Vijay

AU - Chen, Li

AU - Baughn, Linda

AU - Kumar, Shaji

AU - Rajkumar, S. Vincent

AU - Van Ness, Brian G.

N1 - Funding Information: AKM was supported by a grant from the International Myeloma Foundation. We thankfully acknowledge the University of Minnesota Genomics Center and the Minnesota Supercomputing Institute for support with RNA-seq profiling and analysis. This work was further supported by NCI grant# 1U54CA224018-01 (Sub-Project ID: 8404) to BVN.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expression patterns between innate proteasome inhibitor (PI)-sensitive and PI-resistant HMCLs following test dosing with the second-generation PI Ixazomib. We found 1553 genes that changed significantly post treatment in PI-sensitive HMCLs compared with only seven in PI-resistant HMCLs (p < 0.05). Genes that were uniquely regulated in PI-resistant lines were RICTOR (activated), HNF4A, miR-16-5p (activated), MYCN (inhibited), and MYC (inhibited). Ingenuity pathway analysis (IPA) using top kinetic response genes identified the proteasome ubiquitination pathway (PUP), and nuclear factor erythroid 2-related factor 2 (NRF2)-mediated oxidative stress response as top canonical pathways in Ix-sensitive cell lines and patient-derived cells, whereas EIF2 signaling and mTOR signaling pathways were unique to PI resistance. Further, 10 genes were common between our in vitro and ex vivo post-treatment kinetic PI response profiles and Shaughnessy’s GEP80-postBz gene expression signature, including the high-risk PUP gene PSMD4. Notably, we found that heat shock proteins and PUP pathway genes showed significant higher upregulation in Ix-sensitive lines compared with the fold-change in Ix-resistant myelomas.

AB - Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expression patterns between innate proteasome inhibitor (PI)-sensitive and PI-resistant HMCLs following test dosing with the second-generation PI Ixazomib. We found 1553 genes that changed significantly post treatment in PI-sensitive HMCLs compared with only seven in PI-resistant HMCLs (p < 0.05). Genes that were uniquely regulated in PI-resistant lines were RICTOR (activated), HNF4A, miR-16-5p (activated), MYCN (inhibited), and MYC (inhibited). Ingenuity pathway analysis (IPA) using top kinetic response genes identified the proteasome ubiquitination pathway (PUP), and nuclear factor erythroid 2-related factor 2 (NRF2)-mediated oxidative stress response as top canonical pathways in Ix-sensitive cell lines and patient-derived cells, whereas EIF2 signaling and mTOR signaling pathways were unique to PI resistance. Further, 10 genes were common between our in vitro and ex vivo post-treatment kinetic PI response profiles and Shaughnessy’s GEP80-postBz gene expression signature, including the high-risk PUP gene PSMD4. Notably, we found that heat shock proteins and PUP pathway genes showed significant higher upregulation in Ix-sensitive lines compared with the fold-change in Ix-resistant myelomas.

UR - http://www.scopus.com/inward/record.url?scp=85088644623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088644623&partnerID=8YFLogxK

U2 - 10.1038/s41408-020-00344-9

DO - 10.1038/s41408-020-00344-9

M3 - Article

C2 - 32724061

AN - SCOPUS:85088644623

VL - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 7

M1 - 78

ER -